Guggenheim Maintains Buy on CG Oncology, Lowers Price Target to $89
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmitz maintains CG Oncology (NASDAQ:CGON) with a Buy and lowers the price target from $90 to $89.
Guggenheim analyst Michael Schmitz maintains CG Oncology (NASDAQ:CGON) with a Buy and lowers the price target from $90 to $89.